TRCT
AKLI

Tower Research Capital (TRC)’s Akili Inc AKLI Stock Holding History

Tower Research Capital (TRC)’s Portfolio AKLI Stock Details AKLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,900
Closed -$2.87K – 6101
2024
Q1 		$2.87K Sell
9,900
-4,350
-31% -$1.36K ﹤0.01% 4971
2023
Q4 		$6.94K Buy
14,250
+6,855
+93% +$3.16K ﹤0.01% 4684
2023
Q3 		$4.06K Buy
7,395
+1,985
+37% +$1.97K ﹤0.01% 4924
2023
Q2 		$6K Sell
5,410
-6,762
-56% -$8.68K ﹤0.01% 4754
2023
Q1 		$19K Buy
12,172
+7,983
+191% +$12.5K ﹤0.01% 3520
2022
Q4 		$5K Sell
4,189
-10,017
-71% -$17.6K ﹤0.01% 4944
2022
Q3 		$32K Buy
14,206
+12,640
+807% +$90.6K ﹤0.01% 3567
2022
Q2 		$15K Buy
1,566
+690
+79% +$6.81K ﹤0.01% 4105
2022
Q1 		$9K Sell
876
-92
-10% -$907 ﹤0.01% 4513
2021
Q4 		$10K Buy
+968
New +$9.59K ﹤0.01% 4629

Other funds holding AKLI

SCG
Social Capital Group Menlo Park, California $5.16M AUM 66.85% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Tower Research Capital (TRC)'s AKLI Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Akili Inc (AKLI) in Q2 2024, closing a stake of 9,900 shares — an estimated $2.87K sold.

Tower Research Capital (TRC) first reported a position in AKLI in Q4 2021 and held it in 10 quarters. The position peaked at $32K in Q3 2022. 35 funds tracked by Wall St. Rank hold AKLI as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Akili Inc position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,900 Akili Inc shares in Q2 2024, an estimated $2.87K.
  • Tower Research Capital (TRC) first reported a position in Akili Inc in Q4 2021 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Akili Inc position peaked at $32K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Akili Inc as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.